Company
Sumitomo Pharma Am
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
6
4 still marketed
Novel approvals
3
Approvals since 2021
7
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Gemtesa new use Dec 18, 2024
- Orgovyx new use Oct 18, 2024
- Myfembree new use Apr 30, 2024
- Myfembree new use Jan 27, 2023
- Kynmobi new use Sep 22, 2022
- Myfembree new use Aug 5, 2022
- Myfembree approved May 26, 2021
- Gemtesa approved NovelDec 23, 2020
- Orgovyx approved NovelPriority reviewDec 18, 2020
- Kynmobi approved May 21, 2020
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (4)
Newest FDA action first.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.